Survival in chronic hepatitis B. An analysis of 379 patients
- PMID: 6486592
- DOI: 10.7326/0003-4819-101-5-613
Survival in chronic hepatitis B. An analysis of 379 patients
Abstract
Survival data from 379 patients with chronic hepatitis B were analyzed to determine life expectancy for the patient from the time of first contact. One hundred twenty-one patients had chronic persistent hepatitis, 128 had chronic active hepatitis, and 130 had chronic active hepatitis with cirrhosis. The frequency of symptoms (p less than 0.001), stigmata of chronic liver disease (p less than 0.001), and liver function test abnormalities (p less than 0.001) increased as the histologic features worsened, whereas the percentage of patients with circulating hepatitis B DNA polymerase declined (p less than 0.001). Women were uncommon in our series and had less severe disease than men (p less than 0.02). Fifty-one patients had died by the time of this analysis. The estimated 5-year survival rates were 97% for patients with chronic persistent hepatitis, 86% for those with chronic active hepatitis, and 55% for those with chronic active hepatitis with cirrhosis. The usual cause of death was liver failure and its sequelae. A multivariate analysis found age of 40 years or more, total bilirubin level of 1.5 mg/dL or more, ascites, and spider nevi to be factors that identified patients at a higher risk of death. The prognosis for patients with chronic hepatitis B is similar to that for patients with chronic hepatitis of other causes.
Similar articles
-
[Long-term prognosis of chronic B and C viral hepatitis].Leber Magen Darm. 1995 Sep;25(5):205-10. Leber Magen Darm. 1995. PMID: 7500807 German.
-
Natural history and prognostic factors for chronic hepatitis type B.Gut. 1991 Mar;32(3):294-8. doi: 10.1136/gut.32.3.294. Gut. 1991. PMID: 2013423 Free PMC article.
-
Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.Gastroenterology. 1984 Dec;87(6):1222-7. Gastroenterology. 1984. PMID: 6489694 Clinical Trial.
-
[Current therapeutic strategies in hepatocellular carcinoma, Part 1].Leber Magen Darm. 1994 Jul;24(4):150, 153-4. Leber Magen Darm. 1994. PMID: 7934608 Review. German.
-
Long-term follow-up of mild chronic active hepatitis.Acta Gastroenterol Belg. 1987 May-Jun;50(3):341-52. Acta Gastroenterol Belg. 1987. PMID: 2830755 Review. No abstract available.
Cited by
-
Proteomic profiling of HBV infected liver biopsies with different fibrotic stages.Proteome Sci. 2017 Apr 20;15:7. doi: 10.1186/s12953-017-0114-4. eCollection 2016. Proteome Sci. 2017. PMID: 28439208 Free PMC article.
-
Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.Dig Dis Sci. 2009 Jun;54(6):1337-46. doi: 10.1007/s10620-009-0747-y. Epub 2009 Feb 26. Dig Dis Sci. 2009. PMID: 19242792
-
In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother. 1997 Oct;41(10):2076-82. doi: 10.1128/AAC.41.10.2076. Antimicrob Agents Chemother. 1997. PMID: 9333028 Free PMC article.
-
Molecular mechanisms underlying occult hepatitis B virus infection.Clin Microbiol Rev. 2012 Jan;25(1):142-63. doi: 10.1128/CMR.00018-11. Clin Microbiol Rev. 2012. PMID: 22232374 Free PMC article. Review.
-
Update on occult hepatitis B virus infection.World J Gastroenterol. 2016 Oct 21;22(39):8720-8734. doi: 10.3748/wjg.v22.i39.8720. World J Gastroenterol. 2016. PMID: 27818588 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical